Crizanlizumab
Crizanlizumab (pronunciation: kri-zan-li-zu-mab) is a monoclonal antibody medication used for the treatment of sickle cell disease. It is marketed under the brand name Adakveo by Novartis.
Etymology
The name "Crizanlizumab" is derived from the International Nonproprietary Names (INN), which follow specific guidelines for naming monoclonal antibodies. The "-mab" suffix indicates it is a monoclonal antibody, while the "zu" infix denotes its humanized nature. The rest of the name does not carry specific meaning.
Pharmacology
Crizanlizumab is a monoclonal antibody that works by blocking P-selectin, a substance in the blood vessels that causes them to become sticky and leads to the formation of blood clots. By blocking P-selectin, crizanlizumab helps to reduce the frequency of pain crises in people with sickle cell disease.
Usage
Crizanlizumab is used to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. VOCs are a common painful complication of sickle cell disease and are caused by the blockage of blood flow in the vessels.
Side Effects
Common side effects of crizanlizumab include nausea, joint pain, back pain, and fever. Serious side effects may include severe allergic reactions.
See Also
References
- Novartis. (2019). FDA approves Adakveo® (crizanlizumab). Retrieved from https://www.novartis.com/news/media-releases/fda-approves-adakveo-crizanlizumab
- World Health Organization. (2017). International Nonproprietary Names for Pharmaceutical Substances (INN). Retrieved from https://www.who.int/medicines/services/inn/en/
External links
- Medical encyclopedia article on Crizanlizumab
- Wikipedia's article - Crizanlizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski